# OnCo record paper-quazar-aml-001-wei-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-quazar-aml-001-wei-nejm-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-quazar-aml-001-wei-nejm-2020" ;
  schema:name "QUAZAR AML-001: oral azacitidine maintenance for acute myeloid leukaemia in first remission"@en ;
  schema:description "Older adults with acute myeloid leukaemia who took an azacitidine tablet for two weeks of every four after chemotherapy lived a median of ten months longer than those on placebo, with mostly gut side effects and no loss of quality of life."@en ;
  schema:url <https://onco.cc/key-papers/paper-quazar-aml-001-wei-nejm-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2004444>, <https://pubmed.ncbi.nlm.nih.gov/33369355/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2004444> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Wei AH, Döhner H, Pocock C, et al." ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-older-unfit/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/> ;
  onco:trials <https://onco.cc/trials/quazar-aml-001/> ;
  onco:journals <https://onco.cc/journals/nejm/> .